Generics BulletinMabpharm’s CMAB015 proposed biosimilar to Cosentyx (secukinumab) has demonstrated pharmacokinetic equivalence, and comparable safety immunogenicity, to the reference brand, according to the results o
ScripAmid a longer than expected industry downturn, Chinese pharma firms with a solid commercial footing in their home market are now turning to acquiring domestic rights to novel drug assets from their bi
ScripAlkem Laboratories Ltd has launched the first-ever biosimilar cetuximab in India at a significant price differential to Merck KGaA ’s on-market Erbitux, promising to widen access to the therapy for
Generics BulletinSorrento Therapeutics and Mabpharm have revealed plans to take their “biobetter” version of Remicade (infliximab) to markets around the world, after China’s National Medical Product Administration